Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus
- Sponsor
- University at Buffalo
- Study ID
- NCT01299012
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide — DRUGLiraglutide s/c 0.6mg once daily.
Study Details
Evaluating the use of Liraglutide in patients with Type 1 Diabetes.
Key Dates
- Start date
- Oct 31, 2010
- Status verified
- Feb 2017
- Primary completion
- Feb 28, 2013
- Completion
- Jun 30, 2013
Study Design
- Enrollment
- 30 participants (actual)
Primary Outcome Measure
Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide [ Time Frame: 20 weeks ]
Related Studies
- Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft LossRecruiting · Rodolfo Alejandro · Miami, Florida
- Long Term Follow up of Recipients of Functional Islet AllograftsRecruiting · Rodolfo Alejandro · Miami, Florida
- Long Term Surveillance of Islet Transplant Recipients Following Complete Graft LossRecruiting · Rodolfo Alejandro · Miami, Florida
- Type 1 Diabetes Extension StudyRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California